MoonLake Immunotherapeutics MLTX
NASDAQ MLTX
$11.41 -0.06 (-0.52%)
At close: Oct 2, 2026 · 4:00 PM EDT

MoonLake Immunotherapeutics (MLTX) Cash from Discontinued Operations (2022)

Updated

MoonLake Immunotherapeutics (MLTX) recorded Cash from Discontinued Operations of $101 million in Q1 2022.

Analysis

MoonLake Immunotherapeutics (MLTX) Cash from Discontinued Operations (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discont. Ops (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.87 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 MoonLake Immunotherapeutics 971.07 Mn -698.33 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 101.00 Mn
API Access

MoonLake Immunotherapeutics Cash from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-discontinued-operations&ticker=MLTX&period=max&api_key=YOUR_API_KEY